NYSE:CORBF Global Cord Blood (CORBF) Stock Price, News & Analysis $1.05 -0.04 (-3.67%) As of 05/16/2025 03:11 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About Global Cord Blood Stock (NYSE:CORBF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Global Cord Blood alerts:Sign Up Key Stats Today's Range$1.05▼$1.0550-Day Range$0.65▼$1.1552-Week Range$0.25▼$2.00Volume2,300 shsAverage Volume151,443 shsMarket Capitalization$127.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Read More… Receive CORBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Cord Blood and its competitors with MarketBeat's FREE daily newsletter. Email Address CORBF Stock News HeadlinesAdia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell TherapiesMarch 26, 2025 | finance.yahoo.comGlobal Cord Blood’s Liquidation and Court Approval UpdatesDecember 5, 2024 | markets.businessinsider.comWhat is Warren Buffett Hiding?Warren Buffett just poured $40 billion into one quiet sector—and now investors are calling this dividend play the “last retirement stock you’ll ever need.” It’s not a tech company or AI darling. But it’s raking in cash and paying a nearly 8% dividend—even as the broader market stumbles.May 18, 2025 | Behind the Markets (Ad)10 Worst Performing Blue Chip Stocks in 2024October 22, 2024 | insidermonkey.comClinical trial demonstrates effectiveness of drip iron for anemiaSeptember 19, 2024 | msn.comIron given through the vein found to correct anemia in pregnant women faster than iron taken orallySeptember 18, 2024 | msn.comThe vaccines you need to know about before you travelSeptember 17, 2024 | cnn.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines - CORBFJune 24, 2024 | prnewswire.comSee More Headlines CORBF Stock Analysis - Frequently Asked Questions How have CORBF shares performed this year? Global Cord Blood's stock was trading at $1.50 on January 1st, 2025. Since then, CORBF stock has decreased by 30.0% and is now trading at $1.05. View the best growth stocks for 2025 here. How do I buy shares of Global Cord Blood? Shares of CORBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/18/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryHealthcare Current SymbolNYSE:CORBF Previous SymbolNYSE:CORBF CIK1467808 Webwww.globalcordbloodcorp.com Phone852-3605-8180Fax852-3605-8181Employees1,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$196.12 million Price / Sales0.65 Cash Flow$0.75 per share Price / Cash Flow1.40 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares121,550,000Free FloatN/AMarket Cap$127.63 million OptionableNot Optionable Beta-0.68 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSE:CORBF) was last updated on 5/18/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMusk has launched a bold new AI initiative—and while you can’t invest in it directly, one overlooked stock cou...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.